Cell Therapeutics, Inc. provided earnings guidance for the month ended December 31, 2012. For the period, the company expects operating expense of $8,966,000, loss from operations of $8,966,000, EBITDA of $8,393,000, depreciation and amortization of $195,000, interest expense of $1,000 and net loss attributable to common shareholders of $8,589,000. Estimated research and development expenses were $3.6 million for the month of December 2012 respectively.